171611-77-1

Basic information

• Product Name: 17alpha-Acetoxy-9alpha-fluoro-6alpha-methylpregn-4-ene-3,20-dione
• Synonyms: FMPA
• CAS NO: 171611-77-1
• Molecular Formula: C₂₄H₃₃FO₄
• Molecular Weight: 404.52661
• Mol File: 171611-77-1.mol

Chemical Properties

• CAS DataBase Reference: 17alpha-Acetoxy-9alpha-fluoro-6alpha-methylpregn-4-ene-3,20-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 17alpha-Acetoxy-9alpha-fluoro-6alpha-methylpregn-4-ene-3,20-dione(171611-77-1)
• EPA Substance Registry System: 17alpha-Acetoxy-9alpha-fluoro-6alpha-methylpregn-4-ene-3,20-dione(171611-77-1)

Safety Data

• Hazardous Substances Data: 171611-77-1(Hazardous Substances Data)

Upstream product

• 171754-64-6 9α-fluoro-17α-hydroxy-6α-methyl-4-pregnene-3,20-dione 
• 187244-75-3 (6R,8S,9R,10S,13S,14S,17R)-17-Acetyl-9-fluoro-17-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one 
• 113251-88-0 (5S,6R,8S,9S,10R,11S,13S,14S,17R)-17-Acetyl-5,11,17-trihydroxy-6,10,13-trimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-one 
• 187244-73-1 (6R,8S,9S,10R,11S,13S,14S,17R)-17-Acetyl-11,17-dihydroxy-6,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one 
• 106359-98-2 3,3;20,20-bis-ethanediyldioxy-6β-methyl-5α-pregnane-5,11β,17-triol 
• 187244-71-9 C₂₇H₄₀O₇ 
• 99598-75-1 C₂₅H₃₄O₆ 
• 86401-94-7 17α-acetoxy-11β,21-dihydroxy-6α-methyl-1,4-pregnadiene-3,20-dione 
• 806-46-2 11β-acetoxy-17α-hydroxy-4-pregnene-3,20-dione 
• 641-77-0 21-deoxycortisol 
• 83-43-2 Methylprednisolone 
• 171611-80-6 C₂₇H₄₀O₈ 
• 171754-63-5 C₂₆H₄₂O₇ 
• 171611-82-8 C₂₆H₃₉FO₅ 

Relevant articles and documents

Synthesis of a new potent anti-angiogenic agent, 17α-acetoxy-9α- fluoro-6α-methylprogesterone (9α-fluoromedroxyprogesterone acetate [FMPA])

A new anti-angiogenic agent, 17α-acetoxy-9α-fluoro-6α- methylprogesterone (9α-fluoromedroxyprogesterone acetate [FMPA, 9]) was synthesized in a 10-step sequence. FMPA (9) had about two orders of magnitude stronger antiangiogenic activity than medroxyprogesterone acetate (MPA), as estimated in a bioassay involving chorioallantoic membranes of growing chick embryos.

Synthesis and anti-tumor activity of a fluorinated analog of medroxyprogesterone acetate (MPA), 9α-fluoromedroxyprogesterone acetate (FMPA)

We synthesized 9α-fluoromedroxyprogesterone acetate (FMPA) in order to test whether it is a more potent anti-angiogenic agent than medroxyprogesterone acetate (MPA), which has been widely used as a therapeutic agent for breast and endometrium cancers. FMPA was previously synthesized in 10 steps (total yield: 1%). An efficient synthesis of FMPA has been achieved in 6 steps (total yield: 12%). We examined the anti-tumor effect of FMPA, complexed with dimethyl-β-cyclodextrin (DM-β-CyD), on rat mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene (DMBA). FMPA showed great anti-tumor effect on DMBA-induced rat mammary carcinomas.

Progesterone compound and use thereof

A progesterone compound represented by the following formula (1): STR1 ?wherein R1 represents a C1-C23 hydrocarbon group!, and a neovascularization inhibitor containing the same as the active ingredient. The compound (1) has a potent neovascularization inhibitory effect and is hence useful in the treatment of malignant tumors, diabetic retinitis, rheumatism, etc.